Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial

Van Schil P.E., Baas P., Gaafar R., Maat A.P., Van de Pol M., Hasan B., Klomp H.M., Abdelrahman A.M., Welch J., van Meerbeeck J.P.

Source: Eur Respir J 2010; 36: 1362-1369
Journal Issue: December
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Van Schil P.E., Baas P., Gaafar R., Maat A.P., Van de Pol M., Hasan B., Klomp H.M., Abdelrahman A.M., Welch J., van Meerbeeck J.P.. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010; 36: 1362-1369

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Belgian prospective, multicenter, observational study of patients with malignant pleural mesothelioma treated with pemetrexed plus platinum
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014



A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience.
Source: Virtual Congress 2020 – Thoracic surgery: developments in diagnostics and outcomes
Year: 2020


Natural course of asymptomatic malignant pleural effusion in non-small-cell lung cancer patients: a multicenter retrospective study
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020

A randomised trial of active symptom control (ASC) with or without chemotherapy (CT) in the treatment of patients with malignant pleural mesothelioma. First results of the Medical Research Council/British Thoracic Society MS01 trial
Source: Annual Congress 2007 - Pleural malignancy
Year: 2007


Epidemiology, histology and thoracoscopic findings in malignant pleural mesothelioma (MPM) as second tumour in a single-centre cohort
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics
Source: Eur Respir J 2001; 18: Suppl. 33, 319s
Year: 2001

A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011


Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study
Source: Eur Respir J, 50 (6) 1701493; 10.1183/13993003.01493-2017
Year: 2017



Treatment of malignant pleural mesothelioma with combination of carboplatin, caelyx, and gemzitabine: the CCG study of the Nordic mesothelioma group
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014

Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial
Source: Eur Respir J 2007; 30: Suppl. 51, 240s
Year: 2007

Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008

A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002

A phase II trial of lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Systemic treatment of malignant mesothelioma
Source: Eur Respir Mon; 2009: 44: 419–434
Year: 2009

Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008